glp-1 weight loss drug news today october 2025 Popular medications may have health benefits that extend beyond and blood sugar control, a new study finds GLP-1 Weight Loss Drug Market

These results, presented in 2024, provided the first solid evidence that GLP-1 drugs could meaningfully slow Alzheimers in humans

LA acquired the data

Ongoing clinical and mechanistic studies are expected to expand use of GLP-1 receptor agonists, glucose-dependent insulinotropic polypeptide agonists and other metabolic hormones for the treatment of chronic kidney disease

Among GLP1 RA initiators, these percentages were 73% (HbA1c), 36% (eGFR), 31% (LDL cholesterol), and 62% (triglycerides)

Food and Drug Administration: FDAs Concerns With Unapproved GLP-1 Drugs Used for Weight Loss Harvard Health Publishing: Understanding New Weight Loss Drugs The New England Journal of Medicine : TripleHormone-Receptor Agonist Retatrutide for Obesity a Phase 2 Trial Yale Medicine: GLP-1 Weight-Loss Pills: What You Need to Know FDAs Concerns With Unapproved GLP-1 Drugs Used for Weight Loss

On the other hand, several shortcomings of the study should be reported to place the context for interpretation of its findings